IndiumV3, Main, Repository, bibRecord, 001654

Pretargeting vs. direct targeting of human betalox5 islet cells subcutaneously implanted in mice using an anti-human islet cell antibody

Identifieur interne : 001654 ( Main/Repository ); précédent : 001653; suivant : 001655

Pretargeting vs. direct targeting of human betalox5 islet cells subcutaneously implanted in mice using an anti-human islet cell antibody

Auteurs : RBID : Pascal:12-0311871

Descripteurs français

Pascal (Inist)
- Etude comparative, Origine humaine, Capacité fixation, Animal, Souris, Génie biomédical, Médecine nucléaire, Cellule β, Anticorps anti-îlot Langerhans, Ciblage, Dérivé de la morpholine, Indium 111.
Wicri :
- concept : Médecine nucléaire.

English descriptors

KwdEn :
- Animal, Binding capacity, Biomedical engineering, Comparative study, Human origin, Islet cell antibody, Morpholine derivatives, Mouse, Nuclear medicine, Targeting, β Cell.

Abstract

Introduction: We previously demonstrated MORF/cMORF pretargeting of human islets and betalox 5 cells (a human beta cell line) transplanted subcutaneously in mice with the anti-human islet antibody, HPi1. We now compare pretargeting with direct targeting in the beta cell transplant model to evaluate the degree to which target/non-target (T/NT) ratios may be improved by pretargeting. Methods: Specific binding of an anti-human islet antibody HPi1 to the beta cells transplanted subcutaneously in mice was examined against a negative control antibody. We then compared pretargeting by MORF-HPi1 plus ¹¹¹In-labeled cMORF to direct targeting by ¹¹¹In-labeled HPi1. Results: HPi 1 binding to betalox5 human cells in the transplant was shown by immunofluorescence. Normal organ ¹¹¹In backgrounds by pretargeting were always lower, although target accumulations were similar. More importantly, the transplant to pancreas and liver ratios was, respectively, 26 and 10 by pretargeting as compared to 9 and 0.6 by direct targeting. Conclusions: Pretargeting greatly improves the T/NT ratios, and based on the estimated endocrine to exocrine ratio within a pancreas, pretargeting may be approaching the sensitivity required for successful imaging of human islets within this organ.

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 001A44

Links to Exploration step

Pascal:12-0311871

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Pretargeting vs. direct targeting of human betalox5 islet cells subcutaneously implanted in mice using an anti-human islet cell antibody</title>
<author><name>GUOZHENG LIU</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>University of Massachusetts Medical School</s1>
<s2>Worcester, MA 01655</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>University of Massachusetts Medical School</wicri:noRegion>
</affiliation>
</author>
<author><name>SHUPING DOU</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>University of Massachusetts Medical School</s1>
<s2>Worcester, MA 01655</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>University of Massachusetts Medical School</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Akalin, Ali" uniqKey="Akalin A">Ali Akalin</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>University of Massachusetts Medical School</s1>
<s2>Worcester, MA 01655</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>University of Massachusetts Medical School</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rusckowski, Mary" uniqKey="Rusckowski M">Mary Rusckowski</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>University of Massachusetts Medical School</s1>
<s2>Worcester, MA 01655</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>University of Massachusetts Medical School</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Streeter, Philip R" uniqKey="Streeter P">Philip R. Streeter</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Papé Family Pediatric Research Institute, Oregon Health & Science University</s1>
<s2>Portland, OR 97239</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Portland, OR 97239</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Shultz, Leonard D" uniqKey="Shultz L">Leonard D. Shultz</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>The Jackson Laboratory</s1>
<s2>Bar Harbor, ME 06409</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>The Jackson Laboratory</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Greiner, Dale L" uniqKey="Greiner D">Dale L. Greiner</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>University of Massachusetts Medical School</s1>
<s2>Worcester, MA 01655</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>University of Massachusetts Medical School</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="inist">12-0311871</idno>
<date when="2012">2012</date>
<idno type="stanalyst">PASCAL 12-0311871 INIST</idno>
<idno type="RBID">Pascal:12-0311871</idno>
<idno type="wicri:Area/Main/Corpus">001A44</idno>
<idno type="wicri:Area/Main/Repository">001654</idno>
</publicationStmt>
<seriesStmt><idno type="ISSN">0969-8051</idno>
<title level="j" type="abbreviated">Nucl. med. biol.</title>
<title level="j" type="main">Nuclear medicine and biology</title>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal</term>
<term>Binding capacity</term>
<term>Biomedical engineering</term>
<term>Comparative study</term>
<term>Human origin</term>
<term>Islet cell antibody</term>
<term>Morpholine derivatives</term>
<term>Mouse</term>
<term>Nuclear medicine</term>
<term>Targeting</term>
<term>β Cell</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Etude comparative</term>
<term>Origine humaine</term>
<term>Capacité fixation</term>
<term>Animal</term>
<term>Souris</term>
<term>Génie biomédical</term>
<term>Médecine nucléaire</term>
<term>Cellule β</term>
<term>Anticorps anti-îlot Langerhans</term>
<term>Ciblage</term>
<term>Dérivé de la morpholine</term>
<term>Indium 111</term>
</keywords>
<keywords scheme="Wicri" type="concept" xml:lang="fr"><term>Médecine nucléaire</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Introduction: We previously demonstrated MORF/cMORF pretargeting of human islets and betalox 5 cells (a human beta cell line) transplanted subcutaneously in mice with the anti-human islet antibody, HPi1. We now compare pretargeting with direct targeting in the beta cell transplant model to evaluate the degree to which target/non-target (T/NT) ratios may be improved by pretargeting. Methods: Specific binding of an anti-human islet antibody HPi1 to the beta cells transplanted subcutaneously in mice was examined against a negative control antibody. We then compared pretargeting by MORF-HPi1 plus <sup>111</sup>
In-labeled cMORF to direct targeting by <sup>111</sup>
In-labeled HPi1. Results: HPi 1 binding to betalox5 human cells in the transplant was shown by immunofluorescence. Normal organ <sup>111</sup>
In backgrounds by pretargeting were always lower, although target accumulations were similar. More importantly, the transplant to pancreas and liver ratios was, respectively, 26 and 10 by pretargeting as compared to 9 and 0.6 by direct targeting. Conclusions: Pretargeting greatly improves the T/NT ratios, and based on the estimated endocrine to exocrine ratio within a pancreas, pretargeting may be approaching the sensitivity required for successful imaging of human islets within this organ.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0969-8051</s0>
</fA01>
<fA03 i2="1"><s0>Nucl. med. biol.</s0>
</fA03>
<fA05><s2>39</s2>
</fA05>
<fA06><s2>5</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Pretargeting vs. direct targeting of human betalox5 islet cells subcutaneously implanted in mice using an anti-human islet cell antibody</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>GUOZHENG LIU</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>SHUPING DOU</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>AKALIN (Ali)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>RUSCKOWSKI (Mary)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>STREETER (Philip R.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>SHULTZ (Leonard D.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>GREINER (Dale L.)</s1>
</fA11>
<fA14 i1="01"><s1>University of Massachusetts Medical School</s1>
<s2>Worcester, MA 01655</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Papé Family Pediatric Research Institute, Oregon Health & Science University</s1>
<s2>Portland, OR 97239</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>The Jackson Laboratory</s1>
<s2>Bar Harbor, ME 06409</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA20><s1>645-651</s1>
</fA20>
<fA21><s1>2012</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>15597</s2>
<s5>354000506633930060</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2012 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>33 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>12-0311871</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Nuclear medicine and biology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Introduction: We previously demonstrated MORF/cMORF pretargeting of human islets and betalox 5 cells (a human beta cell line) transplanted subcutaneously in mice with the anti-human islet antibody, HPi1. We now compare pretargeting with direct targeting in the beta cell transplant model to evaluate the degree to which target/non-target (T/NT) ratios may be improved by pretargeting. Methods: Specific binding of an anti-human islet antibody HPi1 to the beta cells transplanted subcutaneously in mice was examined against a negative control antibody. We then compared pretargeting by MORF-HPi1 plus <sup>111</sup>
In-labeled cMORF to direct targeting by <sup>111</sup>
In-labeled HPi1. Results: HPi 1 binding to betalox5 human cells in the transplant was shown by immunofluorescence. Normal organ <sup>111</sup>
In backgrounds by pretargeting were always lower, although target accumulations were similar. More importantly, the transplant to pancreas and liver ratios was, respectively, 26 and 10 by pretargeting as compared to 9 and 0.6 by direct targeting. Conclusions: Pretargeting greatly improves the T/NT ratios, and based on the estimated endocrine to exocrine ratio within a pancreas, pretargeting may be approaching the sensitivity required for successful imaging of human islets within this organ.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02T</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Etude comparative</s0>
<s5>07</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Comparative study</s0>
<s5>07</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Estudio comparativo</s0>
<s5>07</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Origine humaine</s0>
<s5>08</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Human origin</s0>
<s5>08</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Origen humano</s0>
<s5>08</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Capacité fixation</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Binding capacity</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Capacidad de fijación</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Animal</s0>
<s5>11</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Animal</s0>
<s5>11</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Animal</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Souris</s0>
<s5>12</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Mouse</s0>
<s5>12</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Ratón</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Génie biomédical</s0>
<s5>13</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Biomedical engineering</s0>
<s5>13</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Ingeniería biomédica</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Médecine nucléaire</s0>
<s5>14</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Nuclear medicine</s0>
<s5>14</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Medicina nuclear</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Cellule β</s0>
<s5>15</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>β Cell</s0>
<s5>15</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Célula β</s0>
<s5>15</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Anticorps anti-îlot Langerhans</s0>
<s5>16</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Islet cell antibody</s0>
<s5>16</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Anticuerpo anti-isla Langerhans</s0>
<s5>16</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Ciblage</s0>
<s5>17</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Targeting</s0>
<s5>17</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Blancado</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Dérivé de la morpholine</s0>
<s2>FR</s2>
<s5>18</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Morpholine derivatives</s0>
<s2>FR</s2>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Indium 111</s0>
<s4>INC</s4>
<s5>86</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fN21><s1>240</s1>
</fN21>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=IndiumV3/Data/Main/Repository

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001654 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Repository/biblio.hfd -nk 001654 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=   *** parameter Area/wikiCode missing *** 
   |area=    IndiumV3
   |flux=    Main
   |étape=   Repository
   |type=    RBID
   |clé=     Pascal:12-0311871
   |texte=   Pretargeting vs. direct targeting of human betalox5 islet cells subcutaneously implanted in mice using an anti-human islet cell antibody
}}

This area was generated with Dilib version V0.5.77.
Data generation: Mon Jun 9 10:27:54 2014. Site generation: Thu Mar 7 16:19:59 2024

	Serveur d'exploration sur l'Indium
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur l'Indium

Pretargeting vs. direct targeting of human betalox5 islet cells subcutaneously implanted in mice using an anti-human islet cell antibody

Pretargeting vs. direct targeting of human betalox5 islet cells subcutaneously implanted in mice using an anti-human islet cell antibody

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri